4 days left! 

26-28 March, 2018
ProArte Maritim Hotel, Berlin, Germany

Day One
Tuesday 27th March, 2018

Day Two
Wednesday 28th March, 2018

Chair’s Opening Remarks

  • Alain Beck Senior Director, Physio-Chemistry Department, Pierre-Fabre

Preclinical & Clinical Safety & Efficacy of a Novel Tumour-Initiating Cell Targeted ADC

  • Scott Dylla Chief Scientific Officer, AbbVie-Stemcentrx


  • Tumour-initiating cells (TIC) underlie tumour growth and recurrence
  • Understanding tumour heterogeneity and TIC identity facilitates novel ADC target discovery
  • Effective targeted killing of TICs should translate into substantial preclinical and clinical activity
  • Careful preclinical determination of a therapeutic index to predict clinical results

The Dolaflexin Platform for High-Loaded Auristatin ADCs


  • The Dolaflexin platform enables high loading of an auristatin derivative, thereby increasing efficacy in low-expressing tumours
  • The auristatin derivative AF-hydroxypropyl-amide (AF-HPA) exerts a controlled bystander effect that improves tolerability
  • XMT-1522 is a HER2-targeted Dolaflexin ADC currently in Phase 1 for patients with Her2+ breast, gastric or lung cancer
  • XMT-1536 is a NaPi2b-targeted Dolaflexin ADC currently in Phase 1 for patients with ovarian or lung cancer
  • More details to follow

BT1718, a Bicycle Toxin Conjugate for the treatment for solid tumours

  • Gavin Bennett Head, Preclinical Development , Bicycle Therapeutics 


  • Bicycle Therapeutics has developed a series of Bicycle Toxin Conjugates, using proprietary Bicyclic peptide technology (Bicycles) to target cytotoxic payloads to tumours.  The small size and hydrophilic nature of Bicycles allow rapid and complete penetration of solid tumours, with rapid renal clearance of unbound conjugate
  • BT1718 binds to MT1-MMP, highly expressed in a range of solid tumours, and associated with aggressive tumour growth and poor outcomes.  BT1718 shows outstanding efficacy, with complete regressions across a range of MT1-MMP expressing models.
  • BT1718 is currently in Ph1 clinical trials in collaboration with Cancer Research UK

Morning Refreshments & Networking

Validating the Next Generation of Tumour Associated Antigens & Formats

Stream Chair: Anette Sommer, Principal Scientist, Bayer 

11.00 Validating the Next Generation of Tumour Associated Antigens & Formats


• The ETB Platform – unique biology around forced internalisation, routing and a novel MOA
• 1st Generation ETB – MT-3724 clinical experience
• 2nd Generation ETBs – enhanced potency and reduced adaptive and innate immunogenicity
• 3rd Generation ETBs – antigen Seeding: a new approach to IO

Eric Poma, Chief Executive Officer & Chief Scientific Officer, Molecular Templates

11.30 uPARAP: A Novel ADC target on Sarcomas & Glioblastomas with Unique Endocytic Properties

  • uPARAP is associated with cancer cells of several rare cancer types
  • uPARAP is a professional endocytic receptor with highly efficient internalization and receptor recycling properties
  • Data demonstrates preclinical proof-of-concept of ADC efficacy in vitro and in vivo

Christoffer Nielsen, Senior Scientist, The Finsen Laboratory

12.00 “Immune Target Atlas” - Identify Novel Therapeutic Targets on Immune Cells Including T & Macrophage Cells

• Learn of an unique technology platform for highly effective target discovery and novel targets
• “Cancer Target Atlas” and “Immune Target Atlas” will fundamentally change the current therapeutic target landscape
• Explore how these technologies will have a tremendous impact on developing more effective and precision cancer immunotherapy

Xun Meng, Chief Executive Officer & Co-Founder, Antibody Discovery & Therapeutics, Abmart

Mitigating Off-Target Toxicity - Preclinical Learnings to Better Inform Clinical Development

Stream Chair: Kurt Gish, Associate Director II, AbbVie

11.00 Clinical and Preclinical Update of Topoisomerase I inhibitor Exatecan Derivative-based ADCs (DXd-ADC)


  • Clinical efficacy of DS-8201, a novel HER2-targeting DXd-ADC
  • Preclinical update of DXd-ADC franchise including IO combination
  • Partnerships with DXd-ADC technology

Daisuke Okajima, Researcher, Daiichi Sankyo

11.30 Preclinical Strategies to Maximise Therapeutic Index of Highly Potent ADCs

  • Leveraging preclinical models to explore exposure response relationships that can inform clinical trial design
  • Evaluating the relationship between stability and toxicity to identify optimal drug to antibody ratios
  • Exploring translatability of preclinical safety findings with highly potent ADCs to the clinic

Mary Jane Hinrichs, Principal Toxicologist, MedImmune

12.00 Application of a PK-PD Modelling & Simulation In Antibody-Drug Conjugate Development

  • Preclinical to clinical translation
  • Bystander effect of ADCs
  • Binding site barrier of ADCs
  • Cell-level pharmacokinetics of ADC

Aman Singh, PK-PD Scientist, Johnson & Johnson

Seamless Supply Chains & Quality Control Strategies to Support Production

Stream Chair: Ian Schwartz, Global Application Delivery Controllers Support & Process Development Consultant, Satorius Stedim

11.00  Antibody Drug Conjugate Process Development & Manufacturing Platform Using Single Use Technologies

  • Single-use manufacturing technologies allow companies to quickly bring GMP manufacturing capability online and with less capital investment
  • Learn about a platform for ADC process development and manufacturing that uses standardized approaches to accelerate development timelines and increase manufacturing predictability while decreasing risks of scale up from development though clinical and commercial manufacture
  • Discuss chemical compatibility of the materials described in the platform to solvents typically used in ADC process

Ian Schwartz, Process Development Consultant, Sartorius Stedim 

11.30 Title to be Confirmed

  • More details to follow

To be Confirmed, PROVEO 

12.00 Panel Discussion: Managing Change Through the Course of ADC Development & Evolution of Methods for Novel Compounds

  • What is the timing for changes with the analytical method and process as compounds advance through testing?
  • What variance is there based on dealing with stochastic vs site specific & highly potent vs payloads of lower activity?
  • As more companies try more things what are the risks/challenges with exposure/cleaning validation with ADCs of varying activity?

Tami Wu, Associate Director, Quality Control, Seattle Genetics

Norbert Schuelke, Senior Director, Head of Purification & Bioconjugation Process Development, Takeda

Lunch & Networking

Review of the ADC Clinical Pipeline


• Update on the key movements in the clinic
• Insight into the rapidly evolving pipeline
• Analysis of novel clinical ADCs

Getting Small to Enhance Targeting: Non-Internalizing Small Molecule-Drug Conjugates for the Treatment of Solid Tumours


• Reviewing experimental evidence for ADCs and SMDCs that suggests that it may be possible to release cytotoxic payloads in the tumour extracellular space
• Exploring CAIX, which is up-regulated in hypoxic cells and is over-expressed in approximately 90% of clear-cell renal cell carcinomas. The protein is known because it does not efficiently internalize upon binding of antibodies or small ligands
• Acetazolamide-based SMDC products may represent a promising class of targeted agents for the treatment of CAIX-positive solid tumours, as single agents or in combination with immunotherapy

Looking to the Future: Exploring the Next Generation Antibody-Drug Conjugate Technologies

Leveraging Prior Knowledge in ADC Product Development & Quality Control

  • Maureen Ryan Senior Director, Antibody Discovery , Seattle Genetics


• Understanding your molecule is critical when it’s as complex as an ADC
• Measuring your CQAs requires multiple complimentary tools
• Managing the diversity of Seattle Genetics’ pipeline of candidates

Targeting Solid Tumors With Potent & Selective Pentarin Miniature Drug Conjugates


  • Pentarins™ are potent and selective miniaturized conjugates that rapidly penetrate deep into solid tumors where they accumulate and release active payloads that drive efficacy
  • Heat Shock Protein 90 (HSP90) expression is increased in tumors and is an intracellular drug conjugate target
  • PEN-866 consists of an HSP90 targeting ligand joined to the payload SN-38 through a cleavable linker that achieves complete and durable tumor regressions in xenograft models of small-cell lung cancer, pancreatic cancer, ovarian cancer and sarcoma.
  • The HSP90 conjugate platform has been expended with other payloads, providing multiple opportunities for novel high value drug conjugates for cancer patients

Afternoon Refreshments & Networking

Where do ADCs sit in the Clinical Landscape? Comparison of ADCs with Current Standard of Care


  • Discuss how the current approved ADCs have or have not changed the therapeutic landscape
  • Explore the ability and/or sequence of ADCs in combination with other therapies

Enhancing Impact of Antibody-Drug Conjugates for Cancer Treatment

  • Maureen Ryan Senior Director, Antibody Discovery , Seattle Genetics


  • More details to follow

Chair’s Closing Remarks

  • Alain Beck Senior Director, Physio-Chemistry Department, Pierre-Fabre